Welcome to our dedicated page for Cue Biopharma news (Ticker: CUE), a resource for investors and traders seeking the latest updates and insights on Cue Biopharma stock.
Cue Biopharma, Inc. reports developments in clinical-stage immunology therapeutics and immune-modulating biologics. Company updates center on its Immuno-STAT platform, the autoimmune and inflammatory disease candidate CUE-401, a clinical-stage dual-mechanism anti-IgE antibody for allergic diseases, and collaboration activity involving B cell depletion programs such as CUE-501.
Recurring news also covers leadership changes, inducement equity awards, shareholder-approved capital actions, research presentations, milestone payments, licensing activity, and other corporate matters tied to Cue Biopharma's Nasdaq-listed common stock and clinical-stage operating model.
On February 22, 2021, Cue Biopharma (NASDAQ: CUE) announced that Dr. Anish Suri, president and chief scientific officer, will present at the 7th Annual Immuno-Oncology 360° Conference on February 25, 2021. He will discuss the Immuno-STAT™ platform, focusing on the CUE-100 series, which includes CUE-101 and CUE-102, targeting T cells for cancer treatments. The presentation aims to show the mechanistic advantages of this approach, offering a novel way to engage T cells in vivo. The event will also include a panel on vaccine expert discussions.
Cue Biopharma has appointed Dr. Matteo Levisetti as Senior Vice President of Clinical Development, effective February 22, 2021. Dr. Levisetti brings extensive experience in drug development from his roles at prominent pharmaceutical companies. He will oversee Cue Biopharma’s ongoing CUE-101 Phase 1 dose escalation trial and the combination trial KEYNOTE-A78, evaluating CUE-101 with KEYTRUDA® for HPV+ R/M HNSCC. Additionally, he will assist in the CUE-102/A02 program targeting WT1 specific T cells. The appointment aims to strengthen the company's immunotherapy pipeline.
On February 1, 2021, Cue Biopharma (Nasdaq: CUE) commenced a Phase 1 dose escalation clinical trial for CUE-101, combined with Merck's KEYTRUDA (pembrolizumab), aimed at treating HPV+ recurrent/metastatic head and neck squamous cell carcinoma. Preliminary results from monotherapy trials indicate CUE-101 is well tolerated and shows early evidence of clinical activity. The trial seeks to explore the synergistic effects of the combination therapy, potentially enhancing anti-tumor responses.
Cue Biopharma (Nasdaq: CUE) announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. A pre-recorded fireside chat will be available for participants starting November 23, 2020, at 10:00 a.m. EST, on the Company’s website. Cue Biopharma is focused on engineering a new class of injectable biologics aimed at selectively engaging and modulating T cells to treat cancer, infectious, and autoimmune diseases using its proprietary platform, Immuno-STAT™.
On November 19, 2020, Cue Biopharma (CUE) announced the extension of its research collaboration with Merck, originally established in 2017, aimed at developing therapies for type 1 diabetes and another autoimmune disease. This extension is supported by promising preclinical data and will provide Cue Biopharma with additional financial research support to further explore biologics aimed at identifying clinical candidates. The company emphasizes the potential of its Immuno-STAT™ platform in targeting T cells effectively within the body.
Cue Biopharma, Inc. (Nasdaq: CUE) reported a business update for Q3 2020, highlighting progress in the Phase 1 trial of CUE-101, now entering cohort 7 dosing at 8mg/kg. The company recorded collaboration revenue of $704,000, down from $984,000 in Q3 2019. Operating expenses rose to $10.8 million, driven by increased clinical activities and R&D costs. Net loss was $10.0 million, compared to a loss of $7.0 million in the prior year. As of September 30, 2020, Cue Biopharma held $91.8 million in cash and marketable securities, expected to fund operations into Q2 2022.
Cue Biopharma (Nasdaq: CUE) has announced participation in two upcoming virtual healthcare conferences: the Stifel Virtual Healthcare Conference on November 18, 2020, and the Jefferies Virtual London Healthcare Conference on November 19, 2020. Presentations will cover the company's Immuno-STAT™ platform, ongoing Phase 1 trial of CUE-101 for HPV16-driven head and neck cancer, and highlight future milestones. Webcasts for both events will be available on Cue Biopharma's website.
Cue Biopharma (Nasdaq: CUE) announced a conference call on November 17, 2020, at 4:30 p.m. EST, to update stakeholders on its business progress. The executive team will discuss findings from cohorts 4, 5, and 6 of its ongoing Phase 1 clinical trial of CUE-101, targeting HPV16-driven head and neck cancer. The call will also cover advancements in technology platforms, pipeline updates, and strategic milestones. Access to live and archived versions of the event will be available on the company's website.
Summary not available.
Summary not available.